Novartis(US:NVS) Ge Long Hui·2025-09-12 09:01Group 1 - Goldman Sachs downgraded Novartis' stock rating from "Neutral" to "Sell," indicating a negative outlook for the stock [1] - The target price for Novartis was slightly reduced from 95.00 CHF to 94.00 CHF, suggesting a weak price trajectory over the next 12 months [1] - Concerns were raised regarding Novartis' growth rate due to increasing competition in the generic drug market, leading to a structural adjustment in overall growth expectations [1] Group 2 - Despite growth concerns, Novartis maintains a strong financial health score, with a revenue growth of 12.95% over the past twelve months [1] - Current trading prices for Novartis are around 101 CHF in Europe and 127.70 USD in the US ADR market [1] - The stock's performance includes a pre-market decline of nearly 3%, with a recent pre-market price of 124.18 USD [1]